

Translation

Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Summary of Consolidated Financial Results for the Three Months Ended December 31, 2022 (Based on Japanese GAAP)

February 9, 2023

Company name: Fuji Pharma Co., Ltd.
 Stock exchange listing: Tokyo
 Stock code: 4554 URL <https://www.fujipharma.jp>
 Representative: President & CEO Takayuki Iwai
 Executive Corporate Officer, General
 Inquiries: Manager, Corporate Planning Department Takeshi Sato TEL 03-3556-3344
 Scheduled date to file Quarterly Securities Report: February 10, 2023
 Scheduled date to commence dividend payments: –
 Preparation of supplementary material on quarterly financial results: Yes
 Holding of quarterly financial results meeting: No

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the three months ended December 31, 2022 (from October 1, 2022 to December 31, 2022)

(1) Consolidated operating results (cumulative)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended December 31, 2022	9,996	5.8	1,190	(23.8)	1,579	(0.1)	1,114	(0.3)
Three months ended December 31, 2021	9,446	1.6	1,562	(8.0)	1,581	(8.7)	1,118	(15.8)

	Earnings per share		Diluted earnings per share	
	Yen		Yen	
Three months ended December 31, 2022	45.88		–	
Three months ended December 31, 2021	46.05		–	

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Millions of yen	Millions of yen	%
As of December 31, 2022	80,698	38,424	47.6
As of September 30, 2022	75,538	35,806	47.4

2. Cash dividends

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen				
Year ended September 30, 2022	–	15.00	–	20.00	35.00
Year ending September 30, 2023	–				
Year ending September 30, 2023 (Forecast)		17.00	–	20.00	37.00

3. Forecast of consolidated financial results for the year ending September 30, 2023 (from October 1, 2022 to September 30, 2023)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending March 31, 2023	20,144	13.6	2,003	(26.1)	2,023	(29.4)	1,476	(19.5)	60.76
Full year	43,311	22.3	4,048	7.2	4,088	9.7	2,974	10.3	122.42

4. Notes

- (1) Changes in significant subsidiaries during the three months ended December 31, 2022
(changes in specified subsidiaries resulting in the change in scope of consolidation): No
- (2) Application of special accounting methods for preparing quarterly consolidated financial statements: No
- (3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
- Changes in accounting policies due to revisions to accounting standards and other regulations: No
- Changes in accounting policies due to other reasons: No
- Changes in accounting estimates: No
- Restatement of prior period financial statements: No

(4) Number of issued shares (common shares)

Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2022	24,753,800 shares	As of September 30, 2022	24,753,800 shares
-------------------------	-------------------	--------------------------	-------------------

Number of treasury shares at the end of the period

As of December 31, 2022	450,913 shares	As of September 30, 2022	459,229 shares
-------------------------	----------------	--------------------------	----------------

Average number of shares during the period (cumulative from the beginning of the fiscal year)

Three months ended December 31, 2022	24,295,385 shares	Three months ended December 31, 2021	24,288,920 shares
--------------------------------------	-------------------	--------------------------------------	-------------------

Quarterly consolidated financial statements
Consolidated balance sheets

(Millions of yen)

	As of September 30, 2022	As of December 31, 2022
Assets		
Current assets		
Cash and deposits	3,546	3,071
Notes receivable - trade	793	2,660
Accounts receivable - trade	11,734	13,773
Merchandise and finished goods	3,714	3,916
Work in process	3,863	3,880
Raw materials and supplies	8,246	8,172
Advance payments to suppliers	769	780
Accounts receivable - other	134	122
Other	1,925	532
Allowance for doubtful accounts	(0)	(0)
Total current assets	34,727	36,909
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	8,187	9,394
Machinery, equipment and vehicles, net	3,820	2,838
Land	1,073	1,072
Leased assets, net	2,219	3,084
Construction in progress	3,016	1,940
Other, net	445	450
Total property, plant and equipment	18,762	18,780
Intangible assets		
Goodwill	691	612
Distributorship	9,053	8,880
Other	660	635
Total intangible assets	10,404	10,128
Investments and other assets		
Investment securities	7,339	10,242
Long-term advance payments	1,574	2,817
Deferred tax assets	1,432	243
Other	1,296	1,576
Total investments and other assets	11,643	14,879
Total non-current assets	40,810	43,788
Total assets	75,538	80,698

(Millions of yen)

	As of September 30, 2022	As of December 31, 2022
Liabilities		
Current liabilities		
Notes and accounts payable - trade	6,249	5,929
Short-term borrowings	8,300	10,300
Advances received	1,471	409
Current portion of long-term borrowings	2,440	2,440
Current portion of bonds payable	–	600
Lease liabilities	377	467
Income taxes payable	444	123
Provision for bonuses	981	347
Provision for bonuses for directors (and other officers)	9	2
Other	3,701	3,231
Total current liabilities	23,975	23,853
Non-current liabilities		
Long-term borrowings	11,193	10,583
Bonds payable	–	2,400
Lease liabilities	2,259	3,095
Retirement benefit liability	1,766	1,813
Other	537	528
Total non-current liabilities	15,756	18,420
Total liabilities	39,732	42,273
Net assets		
Shareholders' equity		
Share capital	3,799	3,799
Capital surplus	4,409	4,409
Retained earnings	26,546	27,173
Treasury shares	(579)	(567)
Total shareholders' equity	34,175	34,814
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	160	2,174
Deferred gains or losses on hedges	16	5
Foreign currency translation adjustment	1,442	1,419
Remeasurements of defined benefit plans	8	7
Total accumulated other comprehensive income	1,627	3,607
Non-controlling interests	2	2
Total net assets	35,806	38,424
Total liabilities and net assets	75,538	80,698

Consolidated statements of income (cumulative) and consolidated statements of comprehensive income (cumulative)

Consolidated statements of income (cumulative)

(Millions of yen)

	Three months ended December 31, 2021	Three months ended December 31, 2022
Net sales	9,446	9,996
Cost of sales	5,441	5,962
Gross profit	4,005	4,034
Selling, general and administrative expenses	2,442	2,843
Operating profit	1,562	1,190
Non-operating income		
Interest income	0	0
Foreign exchange gains	42	26
Donation income	–	110
Gain on valuation of derivatives	–	283
Other	3	13
Total non-operating income	47	434
Non-operating expenses		
Interest expenses	23	24
Bond issuance costs	–	14
Other	4	6
Total non-operating expenses	28	45
Ordinary profit	1,581	1,579
Extraordinary losses		
Loss on retirement of non-current assets	0	–
Total extraordinary losses	0	–
Profit before income taxes	1,581	1,579
Income taxes - current	157	159
Income taxes - deferred	305	305
Total income taxes	462	464
Profit	1,118	1,114
Profit attributable to non-controlling interests	0	0
Profit attributable to owners of parent	1,118	1,114

Consolidated statements of comprehensive income (cumulative)

(Millions of yen)

	Three months ended December 31, 2021	Three months ended December 31, 2022
Profit	1,118	1,114
Other comprehensive income		
Valuation difference on available-for-sale securities	9	2,014
Foreign currency translation adjustment	247	(23)
Deferred gains or losses on hedges	–	(10)
Remeasurements of defined benefit plans, net of tax	(0)	(0)
Total other comprehensive income	255	1,979
Comprehensive income	1,374	3,094
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	1,374	3,094
Comprehensive income attributable to non-controlling interests	0	0